By analyzing the key miRNAs, the corresponding 54 circRNAs and potential disease-targeting drugs such as nitroglycerin to inhibit HIF1A may represent a breakthrough in the treatment of FSGS. The gene discussed is HIF1A; the disease is focal segmental glomerulosclerosis.